Takeda has completed a merger with Shire in Russia

Company Takeda announced the completion of the legal process of the merger with Shire in Russia and the reorganization of the Russian legal entity LLC “Shaer biotech Rus” in the form of joining to “Takeda pharmaceuticals”. The company also outlined plans to bring to the Russian market more than 10 new drugs for 5 years.

“As a result of the reorganization of OOO “Shaer biotech Rus” stopped the activity, and “Takeda pharmaceuticals” has become its legal successor for all liabilities. This kind of changes are administrative procedures on the way to the formation of the United company of Takeda and will not affect the production process, quality, efficiency and safety of the manufactured drugs”, – told in the press service of the Takeda.

On the merger of the Shire Takeda was announced in January 2019. Takeda identified a number of priority therapeutic areas: Oncology, gastroenterology, immunology, neurology, and genetic diseases. Targeted investments are also made in the development of vaccines and drugs in the blood plasma. Thanks to the merger, the company Takeda has expanded its global presence and has taken a leading position in Japan and the United States.

Leave a Reply

Your email address will not be published. Required fields are marked *


For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]